Targeted Agents May Be Moving Closer to Frontline for Treatment of mCRC
October 14th 2019Treatment targeting molecular pathways such as <em>BRAF, </em>HER2<em>,</em> and <em>RAS</em> has typically been reserved for later lines of therapy for patients with metastatic colorectal cancer. Benjamin A. Weinberg, MD, said that agents targeting these pathways are not yet ready for the upfront setting, but data from ongoing trials suggest that these agents may eventually have a role to play in first- and second-line treatment.
Read More
Expert Compares Data for Immunotherapy Versus Chemotherapy In GEJ Cancer
October 14th 2019In an interview with <em>Targeted Oncology</em>, Daniel Catenacci, MD, discussed the clinical trials supporting immunotherapeutic options for patients with GEJ cancer. He also highlighted how physicians can sequence these agents appropriately in their patients.
Read More
Immunotherapy Options Growing for Metastatic Colorectal Cancer
October 14th 2019Immunotherapeutic agents have grown in popularity for treating mismatch repair–deficient metastatic colorectal cancer, becoming the standard of care in the second line, Howard Hochster, MD, told an audience at the 2019 Gastrointestinal Oncology Conference. Furthermore, ongoing clinical trials suggest that these agents may play a larger role in treating CRC going forward.
Read More
Choosing Between Systemic Therapy and TACE for HCC
October 11th 2019What is the ideal first-line therapy for nonresectable, non–transplantable eligible, liver-only hepatocellular carcinoma? In a debate at the 2019 Gastrointestinal Oncology Conference, Mark Yarchoan, MD, had the unenviable task of convincing the audience that systemic therapy was the way to go.
Read More
Neoadjuvant Chemotherapy Prior to Surgery Holds Benefit in Pancreatic Cancer
October 11th 2019In an interview with <em>Targeted Oncology</em>, Michael A. Choti, MD, MBA discussed the treatment landscape for patients with pancreatic cancer, as well as how the role of neoadjuvant chemotherapy in this space is changing. He highlights advantages of neoadjuvant strategies, and also some other treatment options for patients with pancreatic cancer.
Read More
Seeking Answers for Pancreatic Treatment Beyond FOLFIRINOX
October 10th 2019The FOLFIRINOX regimen remains the treatment of choice for patients with pancreatic cancer even as clinical trials exploring potential therapies, including CD40 and CPI-613, offer the possibility of new options for a notoriously difficult-to-treat disease, Davendra P.S. Sohal, MD, MPH, told an audience at the 2019 Gastrointestinal Oncology Conference.
Read More
Molecular Characterization Plays Vital Role in Selecting Optimal Colon Cancer Treatment
November 2nd 2018Al B. Benson III, MD, FACP, FASCO, discusses the treatment landscape for advanced and metastatic CRC and how molecular profiling can play a vital role in selecting the optimal treatment plan for each patient. He also emphasizes the importance of participation in clinical trials to further understand these patients.
Read More
Etiology of HCC Plays a Critical Role in Treatment Choice as Landscape Grows, Says Mody
November 2nd 2018Kabir Mody, MD, discusses the evolution of the hepatocellular carcinoma treatment landscape over the past year during a presentation at the 2018 International Society of Gastrointestinal Oncology.
Read More